InGeneron Publishes Landmark Study Demonstrating Structural Tendon Regeneration with Autologous Cell Therapy System

Houston, TX, USA, July 23, 2025 – InGeneron, Inc., a biotechnology company pioneering autologous regenerative cell therapies, today announced the publication of a pivotal preclinical study in the International Journal of Molecular Sciences , further validating the regenerative mechanism of its proprietary cell therapy platform for tendon repair. The study, titled “ Regeneration of Biomechanically Functional Tendon Tissue Following Injection of Uncultured, Autologous, Adipose-Derived Regenerative Cells [UA-ADRCs] into Partial Achilles Tendon Defects in Rabbits “, provides robust evidence that InGeneron’s cell therapy restores functional tendon architecture, a key milestone in the company’s scientific narrative. This publication completes a decade-long body of work establishing the full mechanism of action for InGeneron’s therapeutic approach. In contrast to other cell therapy players, InGeneron is now the only company to have validated every step of its therapeutic hypothesis through peer-reviewed data: Cell Characterization: Demonstrated consistent and reproducible cellular composition of ADRCs across age, sex, BMI, and ethnicity – Schmitz et al., Cells . 2023;12:30 In Vivo Regeneration: Proved functional tissue regeneration in animal models with histology and biomechanical testing, as shown in this newly published study – Schmitz et al., Int. J. Mol. Sci. 2025;26:6800 Human Biopsy Evidence: Published first-in-human histological confirmation of tendon regeneration – Alt et al., World J Stem Cells . 2021;13(7):944–970 Clinical Trial Data: Reported statistically significant, long-term improvements in pain and function in patients with partial-thickness rotator cuff tears – Hurd et al., J Orthop Surg Res . 2020;15:122 ; Lundeen et al., Sci Rep . 2023;13:19348 “This study confirms what we’ve set out to prove for years — that our therapy does not just alleviate symptoms, it restores tissue,” said Dr. Eckhard Alt, Founder and Executive Chairman of InGeneron and senior author of the study. “This is the kind of disease-modifying evidence that regenerative medicine has promised but rarely delivered.” In the controlled study, partial-thickness Achilles tendon defects were surgically created in rabbits and treated with either saline or a single injection of freshly isolated UA-ADRCs. Animals treated with UA-ADRCs showed: Newly formed, organized tendon-like tissue Histologic and immunohistochemical signatures of true tendon regeneration rather than scar formation Significantly improved biomechanical viscoelasticity compared to sham-treated animals Co-author Dr. Nicola Maffulli, a globally recognized expert in tendon biology, added: “We are delighted that our work has been published in a high-impact scientific journal. Tendon ailments affect millions of people, often compromising mobility and quality of life. Regenerative medicine has made bold promises in the past, but we now have strong evidence that this approach can truly heal tendon lesions. These seminal findings provide a scientific bridge to clinical applications, and with the support of InGeneron and our international research collaboration, we are confident that patients and athletes will benefit.” The UA-ADRCs used in the study were isolated using InGeneron’s Transpose Ultra ® System, enabling same-day, point-of-care therapy. Unlike cultured or genetically modified therapies, InGeneron’s approach uses unmodified, freshly isolated autologous cells, preserving biological potency and improving safety. Publication Details Schmitz, C. et al. (2025). Regeneration of Biomechanically Functional Tendon Tissue Following Injection of Uncultured, Autologous, Adipose-Derived Regenerative Cells into Partial Achilles Tendon Defects in Rabbits. International Journal of Molecular Sciences , 26(14), 6800. https://doi.org/10.3390/ijms26146800 About InGeneron InGeneron is a biotechnology company developing novel, safe, and evidence-based cell therapies. We are setting new therapeutic standards by enabling minimally invasive treatments that unlock the healing potential of each patient’s own regenerative cells, processed at the point of care for same-day treatment. We currently focus on helping patients impacted by orthopedic conditions and are conducting several clinical trials to further validate our technology as a disease-modifying treatment. Backed by more than 20 years of research and a growing body of clinical evidence, we are committed to advancing safe, effective, and disease-modifying therapies that improve long-term patient outcomes. InGeneron’s CE-marked Transpose Ultra ® System is commercially available in the EU. In the U.S., it is available for investigational use only and remains under clinical evaluation in several FDA-approved trials. www.ingeneron.com InGeneron, Inc. Eckhard Alt, MD, PhD Executive Chairman of InGeneron +1 (713) 440 9900 [email protected] Media Inquiries Marcus DeAyala Director, Corporate Development and Strategy [email protected] Recent Posts Press Releases Feb 4, 2026 InGeneron, Inc. Announces EU Quality Management System Certificate Under MDR Regulation (EU) 2017/745 for Medical Devices Press Releases Jul 23, 2025 InGeneron Publishes Landmark Study Demonstrating Structural Tendon Regeneration with Autologous Cell Therapy System Press Releases Nov 13, 2023 InGeneron Reports Positive Long-Term Results for its Cell Therapy in Partial-Thickness Rotator Cuff Tears Press Releases Nov 3, 2023 InGeneron Announces Encouraging Results from Emory University’s 480-Patient Phase III Knee Osteoarthritis Trial Press Releases Jan 6, 2023 New Study Reports Broad Applicability of InGeneron’s Regenerative Cell Therapy System Across Patient Groups Press Releases Jan 24, 2022 InGeneron Publishes Overview on Current State and Potential of Regenerative Cell Therapy in Orthopedics Press Releases Jan 6, 2022 American Medical Association Issues New CPT® Category III Codes for InGeneron’s Cell Therapy for Rotator Cuff Tears News Nov 23, 2021 InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body Press Releases Jul 23, 2021 InGeneron Reports First-In-Human Microscopic Evidence of Adult Tendon Regeneration Following Autologous Stem Cell Treatment Press Releases Apr 7, 2020 InGeneron Announces Publication of Rotator Cuff Feasibility Study Press Releases Oct 31, 2019 InGeneron Announces Publication of Preclinical Results for its Cell Therapy in Chronic Ischemic Heart Failure News Jun 11, 2019 InGeneron Extends Series D Financing to $43 Million to Bring Regenerative Cell Therapy into the Clinic Press Releases May 15, 2019 InGeneron Initiates Pivotal Study for its Clinical Lead Program in Rotator Cuff Tendinopathy Press Releases Mar 21, 2019 InGeneron Announces Publication of Results from First-in-Human Case Report of its Cell Therapy in Bone Regeneration News Jan 23, 2019 InGeneron Expands Development Pipeline with Two Osteoarthritis Programs News Dec 12, 2018 InGeneron Reports Positive Top-Line Data From its Clinical Lead Program in Rotator Cuff Tendinopathy News Sep 18, 2017 InGeneron Announces Publication of Positive Results from Investigator-Initiated Wound Healing Case Series Using Company’s Regenerative Cell Technology News Mar 6, 2017 InGeneron Completes Strategic Financing from Sanford Health to Advance Regenerative Cell Therapies News Dec 5, 2016 InGeneron Establishes Presence in Cambridge, MA and Initiates Collaboration with German Accelerator Life Sciences News Nov 21, 2016 InGeneron Announces Presentation of Results from Investigator Initiated Case Series of its Regenerative Cell Therapy in Chronic Back Pain at IFATS Have any Questions ? Important In the US InGeneron’s Transpose ® RT cell therapy platform is for investigational use only. By Clicking ‘Continue’ I confirm acknowledgment Continue Our mission is to enable novel, safe, and evidence-based therapies by unlocking the healing potential of each patient’s own regenerative cells. Twitter Linkedin Facebook 2 Youtube InGeneron, Inc. 8205 El Rio St Houston, TX 77054 USA +1 (713) 440 9900 [email protected] Subscribe to our Newsletter © 2026 by InGeneron, Inc. Site info . All rights reserved. Web Design & Development by BelugaLab Privacy Policy

The release as fetched from its publisher. ingeneron.com ↗